Hot Investor Mandate 1: Firm Raises New Impact Fund For Early Stage Oncology Drugs

26 May

A venture capital firm with offices in Boston, Massachusetts and San Francisco, California has raised a $470 million oncology impact fund through a joint venture. The firm typically makes investments ranging from $3 to $25 million depending on the target company’s stage of development and capital requirements. The firm will consider investment into companies located anywhere around the globe. The firm makes 3-4 new investments annually.

The firm is currently focused on companies developing therapeutics, in particular oncology and regenerative medicine, however they will also consider investments into companies developing platform technologies. While the firm considers investment from seed stage to PIPE (private investment in public equity) the firm’s ideal company has an asset that is pre-clinical or in early clinical trials.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: